FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:FRX - CA31447P1009 - Common Stock
10.39 CAD
-0.08 (-0.76%)
We assign a fundamental rating of 3 out of 10 to FRX. FRX was compared to 22 industry peers in the Biotechnology industry. FRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FRX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
FRX had negative earnings in the past year.
FRX had a negative operating cash flow in the past year.
In the past 5 years FRX always reported negative net income.
FRX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
FRX has a Return On Assets of -14.09%. This is in the better half of the industry: FRX outperforms 77.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.09% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FRX has a Gross Margin of 93.12%. This is amongst the best in the industry. FRX outperforms 100.00% of its industry peers.
The Profit Margin and Operating Margin are not available for FRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.12% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for FRX has been increased compared to 1 year ago.
FRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, FRX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.15, we must say that FRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FRX (-2.15) is better than 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.15 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
FRX has a Current Ratio of 4.69. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
FRX has a better Current ratio (4.69) than 77.27% of its industry peers.
A Quick Ratio of 4.44 indicates that FRX has no problem at all paying its short term obligations.
FRX has a better Quick ratio (4.44) than 77.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.69 | ||
| Quick Ratio | 4.44 |
3. Growth
3.1 Past
The earnings per share for FRX have decreased strongly by -475.00% in the last year.
The Revenue for FRX has decreased by -21.39% in the past year. This is quite bad
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%
3.2 Future
The Earnings Per Share is expected to grow by 240523.00% on average over the next years. This is a very strong growth
Based on estimates for the next years, FRX will show a very strong growth in Revenue. The Revenue will grow by 24.44% on average per year.
EPS Next Y-275620297195074240%
EPS Next 2Y10962228212.58%
EPS Next 3Y26670700%
EPS Next 5Y240523%
Revenue Next Year-22.32%
Revenue Next 2Y16.66%
Revenue Next 3Y17.6%
Revenue Next 5Y24.44%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
FRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 11.29, the valuation of FRX can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FRX indicates a rather cheap valuation: FRX is cheaper than 95.45% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of FRX to the average of the S&P500 Index (23.83), we can say FRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.29 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as FRX's earnings are expected to grow with 26670700.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10962228212.58%
EPS Next 3Y26670700%
5. Dividend
5.1 Amount
No dividends for FRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:FRX (12/17/2025, 7:00:00 PM)
10.39
-0.08 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners45.49%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap354.82M
Revenue(TTM)38.79M
Net Income(TTM)-6.94M
Analysts85.45
Price Target19.53 (87.97%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-95.59%
Min EPS beat(2)-199.56%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)-67.7%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-157.9%
EPS beat(12)5
Avg EPS beat(12)-104.64%
EPS beat(16)6
Avg EPS beat(16)-92.56%
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)8.54%
Revenue beat(4)2
Avg Revenue beat(4)-10.17%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)8.54%
Revenue beat(8)4
Avg Revenue beat(8)-7.28%
Revenue beat(12)6
Avg Revenue beat(12)2.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.41%
PT rev (3m)-1.95%
EPS NQ rev (1m)-68.13%
EPS NQ rev (3m)-73.51%
EPS NY rev (1m)-107.76%
EPS NY rev (3m)-262.34%
Revenue NQ rev (1m)-9.01%
Revenue NQ rev (3m)-9.07%
Revenue NY rev (1m)-1.66%
Revenue NY rev (3m)-6.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.29 | ||
| P/S | 6.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.32
EYN/A
EPS(NY)0.92
Fwd EY8.85%
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS1.57
BVpS-0.18
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.09% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.12% | ||
| FCFM | N/A |
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.69 | ||
| Quick Ratio | 4.44 | ||
| Altman-Z | -2.15 |
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
EPS Next Y-275620297195074240%
EPS Next 2Y10962228212.58%
EPS Next 3Y26670700%
EPS Next 5Y240523%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%
Revenue Next Year-22.32%
Revenue Next 2Y16.66%
Revenue Next 3Y17.6%
Revenue Next 5Y24.44%
EBIT growth 1Y-340.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year863.44%
EBIT Next 3Y338.18%
EBIT Next 5YN/A
FCF growth 1Y60.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.53%
OCF growth 3YN/A
OCF growth 5YN/A
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What is the ChartMill fundamental rating of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA.
Can you provide the valuation status for FENNEC PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 3 / 10 to FENNEC PHARMACEUTICALS INC (FRX.CA). This can be considered as Overvalued.
What is the profitability of FRX stock?
FENNEC PHARMACEUTICALS INC (FRX.CA) has a profitability rating of 1 / 10.
How financially healthy is FENNEC PHARMACEUTICALS INC?
The financial health rating of FENNEC PHARMACEUTICALS INC (FRX.CA) is 4 / 10.